终身疟疾暴露成人中GMZ2疟疾疫苗的受控人类疟疾感染研究
在50名终身暴露于恶性疟原虫的加蓬健康成人中,评估了无性血液期疟疾疫苗GMZ2(30或100 µg,CAF01或Alhydrogel佐剂)的安全性和免疫原性,并对35人进行受控人类疟疾感染(CHMI)。所有GMZ2组抗体水平均高于对照,但CHMI显示既往接种GMZ2无保护效果;基线疫苗特异性抗体浓度与抗疟保护相关。
要点
- GMZ2在终身疟疾暴露成人中耐受良好且具免疫原性,不同制剂抗体反应相似。
- CHMI显示既往接种GMZ2未产生保护效果,各组疟疾发生比例和时间为相似。
- 基线疫苗特异性抗体浓度与抗疟保护相关,提示预存免疫的重要性。
核心结论
- GMZ2在终身暴露于恶性疟原虫的加蓬成人中耐受良好且具免疫原性,但CHMI未显示既往接种GMZ2的保护效果。
- 基线疫苗特异性抗体浓度与抗疟保护相关。
研究设计与样本
- 50名终身暴露于恶性疟原虫的健康成人志愿者随机接种3次(间隔4周)30或100 µg GMZ2/CAF01、100 µg GMZ2/Alhydrogel或对照疫苗Verorab。
- 末次接种约13周后,35/50名志愿者通过直接静脉接种3200个Pf sporozoites(Sanaria® PfSPZ Challenge)进行CHMI。
主要发现
- 不良事件在GMZ2组与对照组间分布相似。
- 末次接种后4周,3个GMZ2组的基线校正抗GMZ2抗体浓度均高于对照组,各GMZ2制剂诱导的抗体水平相似。
- CHMI后29/34(85%)志愿者出现Pf疟原虫血症,15/34(44%)发生疟疾(疟原虫血症加症状)。
- 疟疾发生比例(对照组2/5,GMZ2-Alhydrogel组6/10,30 µg GMZ2-CAF01组2/8,100 µg GMZ2-CAF01组5/11)及发生时间在各组间相似。
- 基线疫苗特异性抗体浓度与抗疟保护相关。
关键数值与推荐
- CHMI后疟原虫血症29/34(85%),疟疾15/34(44%)。
- 疟疾发生比例:对照2/5,GMZ2-Alhydrogel 6/10,30 µg GMZ2-CAF01 2/8,100 µg GMZ2-CAF01 5/11。
临床怎么用
- GMZ2单用在该人群中未显示保护效果,不支持直接推进至 efficacy 试验。
- 基线疫苗特异性抗体浓度与保护相关,提示疫苗设计需考虑诱导更高基线抗体水平。
- CHMI用PfSPZ Challenge是非洲验证无性血液期疟疾疫苗的有效新工具。
局限性
- CHMI仅35/50名志愿者参与,各组样本量小(如对照组仅5人)。
- 研究对象为终身疟疾暴露的加蓬成人,结论外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GMZ2 is a recombinant malaria vaccine inducing immune responses against Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We used standardized controlled human malaria infection (CHMI) to assess the efficacy of this asexual blood-stage vaccine. METHODS: We vaccinated 50 healthy, adult volunteers with lifelong exposure to Pf 3 times, at 4-week intervals, with 30 or 100 µg GMZ2 formulated in CAF01, a liposome-based adjuvant; 100 µg GMZ2, formulated in Alhydrogel; or a control vaccine (Verorab). Approximately 13 weeks after the last vaccination, 35/50 volunteers underwent CHMI by direct venous inoculation of 3200 Pf sporozoites (Sanaria® PfSPZ Challenge). RESULTS: Adverse events were similarly distributed between GMZ2 and control vaccinees. Baseline-corrected anti-GMZ2 antibody concentrations 4 weeks after the last vaccination were higher in all 3 GMZ2-vaccinated arms, compared to the control group. All GMZ2 formulations induced similar antibody levels. CHMI resulted in 29/34 (85%) volunteers with Pf parasitemia and 15/34 (44%) with malaria (parasitemia and symptoms). The proportion of participants with malaria (2/5 control, 6/10 GMZ2-Alhydrogel, 2/8 30 µg GMZ2-CAF01, and 5/11 100 µg GMZ2-CAF01) and the time it took them to develop malaria were similar in all groups. Baseline, vaccine-specific antibody concentrations were associated with protection against malaria. CONCLUSIONS: GMZ2 is well tolerated and immunogenic in lifelong-Pf-exposed adults from Gabon, with similar antibody responses regardless of formulation. CHMI showed no protective effect of prior vaccination with GMZ2, although baseline, vaccine-specific antibody concentrations were associated with protection. CHMI with the PfSPZ Challenge is a potent new tool to validate asexual, blood-stage malaria vaccines in Africa. CLINICAL TRIALS REGISTRATION: Pan-African Clinical Trials: PACTR201503001038304.
引用
- Dejon-Agobe JC, Ateba-Ngoa U, Lalremruata A, et al. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2. Clin Infect Dis. 2019. PMID: 30561539. doi:10.1093/cid/ciy1087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。